XKRX
199800
Market cap443mUSD
Aug 16, Last price
75,300.00KRW
Name
ToolGen Inc
Chart & performance
P/E
—
P/S
455.95
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.06%
Rev. gr., 5y
12.87%
Revenues
1.31b
+46.63%
Net income
-36.76b
L
CFO
-20.22b
L+22.85%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ToolGen Inc. is a biotechnology firm dedicated to the research and development of cutting-edge genome editing technologies. The company supplies a variety of ready-to-use reagents for gene engineering experiments, including purified gRNA/Cas9, standard gRNA/Cas9, and recombinant Cas9 protein. Beyond its product offerings, ToolGen also provides specialized services such as the creation of genome-edited cell lines, genetically modified mice/rats, and altered plants, in addition to performing surrogate reporter synthesis and in-del analysis.
Key people
Ji Hak Han
Managing Director
Seok Jung Kim
Assistant Managing Director
Yu Ri Kim
Vice President, Chief Legal Officer, Director · since 2022
Gyeong Seong Min
Internal Auditor, Director · since 2019
Yil Ho Ha
Other Non-Executive Director · since 2020
Other Non-Executive Director · since 2024
Jin Su Kim
Other Non-Executive Director · since 2024
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||